GLP Watchdog

Best Tirzepatide Providers at 5mg in 2026: Ranked and Reviewed

A seller reaches this table only by publishing a tirzepatide price at 5mg, the step-up dose tier. That single filter shortens the list considerably, and it is worth knowing what it hides: a seller may well carry tirzepatide and simply never name this strength on a price page. What you see below is the advertised figure, the date behind it, and our score.

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
Price and states served both move. Read them off the seller's own site before you enroll.How our reviews work →

Methodology & sources

Each provider here carries a score from our published six-factor rubric[1], and the list is then cut down to the dose named in the page title.

Published Phase 3 efficacy for tirzepatide (~20.9% mean weight loss at the 15 mg dose over 72 weeks) comes from the SURMOUNT-1 trial[2]. The SURMOUNT-5 head-to-head published in 2025 directly compared tirzepatide and semaglutide[3].

The same filter is run at the other doses we rank: 2.5mg, 7.5mg and 10mg, and brand-name tirzepatide has its own ranking of brand sellers.

Nothing matches this filter yet. We are still backfilling the price records behind it.

Frequently Asked Questions

Work from the dated figures in the table, not from a number in a paragraph. Compounded rows and brand rows sit a long way apart, and neither is a quote. Lab work, shipping, and the consultation can be billed on top, and a promotional opening month is not the standing rate.
Sources & methodology — as of November 2026
  1. 1.GLP Watchdog — GLP-1 Pricing Index 2026 (our independent dataset)— GLP Watchdog.
  2. 2.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
  3. 3.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Aronne LJ et al.)— New England Journal of Medicine.PMID: 40353578.